Optiscan Imaging Ltd
ASX:OIL
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.072
0.255
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Optiscan Imaging Ltd
Optiscan Imaging Ltd
PP&E Net
Optiscan Imaging Ltd
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Optiscan Imaging Ltd
ASX:OIL
|
PP&E Net
AU$407.3k
|
CAGR 3-Years
-16%
|
CAGR 5-Years
12%
|
CAGR 10-Years
35%
|
|
|
R
|
Respiri Ltd
ASX:RSH
|
PP&E Net
AU$117k
|
CAGR 3-Years
-10%
|
CAGR 5-Years
65%
|
CAGR 10-Years
2%
|
|
|
ImpediMed Ltd
ASX:IPD
|
PP&E Net
AU$1.4m
|
CAGR 3-Years
12%
|
CAGR 5-Years
50%
|
CAGR 10-Years
22%
|
|
|
C
|
Cyclopharm Ltd
ASX:CYC
|
PP&E Net
AU$10.4m
|
CAGR 3-Years
22%
|
CAGR 5-Years
9%
|
CAGR 10-Years
42%
|
|
|
Cochlear Ltd
ASX:COH
|
PP&E Net
AU$517.2m
|
CAGR 3-Years
6%
|
CAGR 5-Years
25%
|
CAGR 10-Years
21%
|
|
|
EMvision Medical Devices Ltd
ASX:EMV
|
PP&E Net
AU$523.1k
|
CAGR 3-Years
18%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Optiscan Imaging Ltd
Glance View
Optiscan Imaging Ltd. is engaged in the development of endomicroscopic imaging technologies for medical, translational and pre-clinical applications. The company is headquartered in Mulgrave, Victoria. The firm has developed and commercialized confocal microscopes for clinical and pre-clinical applications. Its endomicroscopic technology enables 3D, in-vivo imaging of human tissue at the cellular level for cancer screening, diagnoses and in surgery. Its InVivage device is developed for clinical use in the oral cancer and other cancer applications. Its Fluorescence In Vivo Endomicroscopy (FIVE2) also known as ViewnVivo system, is a miniaturised confocal endomicroscope used for cellular level in-vivo imaging in living tissues. The firm also provides customization options for its product, (FIVE2).
See Also
What is Optiscan Imaging Ltd's PP&E Net?
PP&E Net
407.3k
AUD
Based on the financial report for Jun 30, 2024, Optiscan Imaging Ltd's PP&E Net amounts to 407.3k AUD.
What is Optiscan Imaging Ltd's PP&E Net growth rate?
PP&E Net CAGR 10Y
35%
Over the last year, the PP&E Net growth was -29%. The average annual PP&E Net growth rates for Optiscan Imaging Ltd have been -16% over the past three years , 12% over the past five years , and 35% over the past ten years .
You don't have any saved screeners yet
